FDA to Phase Out Artificial Dyes: What You Need to Know
Black America Web Featured Video
CLOSE
Source: Scott Olson / Getty
The Food and Drug Administration (FDA) has announced a major policy shift that will affect some of the most colorful snacks on store shelves.
Popular items like Flamin' Hot Cheetos, Skittles, and Mountain Dew Baja Blast will soon be reformulated as the FDA phases out petroleum-based synthetic dyes.
Here's a breakdown of what you need to know:
The FDA plans to eliminate six synthetic dyes from the U.S. food supply by the end of next year.
This includes: Red 40
Yellow 5
Yellow 6
Blue 1
Blue 2
Green 2
Red Dye 3, previously given a longer timeline, is now also expected to be phased out by the end of 2026.
This policy directly affects products that rely on vibrant synthetic colors, including: Flamin' Hot Cheetos
Skittles
Trix Cereal
Mountain Dew Baja Blast
Froot Loops
And many more from brands like PepsiCo, General Mills, Mars, and WK Kellogg.
The FDA recommends that food manufacturers switch to natural coloring options, such as: Watermelon juice
Beet juice
Carrot juice
These alternatives, while often more expensive, are considered safer for long-term health.
FDA Commissioner Marty Makary cited growing evidence linking artificial dyes to hyperactivity in children and other health concerns.
The move follows years of pressure from health advocates and consumer groups.
Though there isn't a strict ban in place, the FDA and food industry have an understanding.
The agency plans to enforce a national timeline and is exploring all available tools to ensure compliance.
U.S. Health Secretary Robert F. Kennedy Jr. is leading the charge, claiming food and drug industry corruption has made Americans less healthy.
He aims to prioritize nutrition over pharmaceuticals.
In past years, companies like Kraft Heinz reformulated products like mac and cheese to use natural dyes.
Others, like General Mills, temporarily switched but reverted due to poor consumer response.
Companies that help food brands reformulate recipes are now in high demand. McCormick has reported an uptick in activity as more manufacturers look to replace synthetic colors and reduce sodium.
While natural colors are generally more costly to produce, Makary claims this shift shouldn't significantly impact consumer prices, pointing to other countries where similar changes have been implemented successfully. Spring 2025 : FDA begins revoking authorization of synthetic dyes
: FDA begins revoking authorization of synthetic dyes End of 2025 : Red Dye 3 phased out
: Red Dye 3 phased out End of 2026 : Remaining six dyes removed from market
: Remaining six dyes removed from market Ongoing: Approval and rollout of natural dye alternatives
SEE ALSO
FDA to Phase Out Artificial Dyes: What You Need to Know was originally published on b1057.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
6 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
Yahoo
6 hours ago
- Yahoo
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
A drug used to treat insomnia has protected mice against the buildup of the tau protein found to clump abnormally in neurodegenerative diseases like Alzheimer's. This could lead to new ways to help slow the progress of these diseases. An increasing number of people are facing cognitive decline personally or in their loved ones. There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still few treatment options that provide clear benefits. So due to the links between Alzheimer's and poor sleep, Washington University neurologist Samira Parhizkar and colleagues investigated a central nervous system depressant, lemborexant, that was approved for use as a sleep aid by the FDA in December 2019. "We have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer's and several related disorders," explains Washington University neurologist David Holtzman. The role of amyloid beta proteins in Alzheimer's has been controversial, but they're not the only proteins implicated in the disease. Tau proteins normally contribute to the structure of brain cells, but past research has linked abnormal ones with the rate of brain atrophy in animal models. "The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer's dementia are helpful, but they don't slow the disease down as much as we would like," says Holtzman. "We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further." But when the researchers compared lemborexant with another sleep aid, zolpidem, the results were unexpected. Mice receiving lemborexant retained up to 40 percent more volume in their memory-forming hippocampus than those who received zolpidem or no sleep aid at all. "What was surprising was that these effects were not seen with a standard sleep drug like zolpidem, which increases NREM sleep similarly to lemborexant," Parhizkar told Eric Dolan at PsyPost. "This suggests that the benefit is not just about more sleep, but rather how that sleep is promoted." The two sleep drugs work on different mechanisms, and that seems to be key to the protective effects. Lemborexant blocks orexin, a neuropeptide that regulates the sleep cycle, and when the team genetically knocked out orexin receptor 2 in mice, it reduced the buildup of tau in their brains. Strangely, though, the protective results of lemborexant were only seen in male mice, even though females were also tested. What's more, mouse studies don't always produce the same results in humans. Lemborexant has only been approved for short-term use in humans, so its long-term impacts as well as effectiveness in tau reduction still need to be investigated. While many questions remain to be answered, if the results seen in this study hold true, the researchers hope early intervention with a drug like lemborexant could potentially delay the progression of neurodegeneration. This research was published in Nature Neuroscience. Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach
Forbes
8 hours ago
- Forbes
CDC Vaccine Advisors To Vote On Thimerosal In Flu Shots. Here's What To Know About Thimerosal
ATLANTA, GA - OCTOBER 05: A podium with the logo for the Centers for Disease Control and Prevention ... More at the Tom Harkin Global Communications Center on October 5, 2014 in Atlanta, Georgia. (Photo by Kevin C. Cox/Getty Images) The CDC's Advisory Committee on Immunization Practices is set to vote later this week on the issue of thimerosal in flu vaccines. What exactly is thimerosal and is it actually harmful for people that take vaccines containing the substance? Thimerosal is a mercury-based organic preservative that historically was put in several vaccines in low quantities in order to prevent the growth of harmful bacteria and fungi, particularly when multi-dose vials were used. Vaccines can become accidentally contaminated, as may occur with multiple needle punctures with multi-dose vials. Before the late 1990's, infants were recommended to receive three vaccines that contained thimerosal- hepatitis B, Haemophilus influenzae type b and diphtheria-tetanus-acellular pertussis. There are no known health risks associated with thimerosal at the concentrations used in vaccines, according to the FDA. Secretary of Health and Human Services Robert F. Kennedy Jr. disagrees. In his 2014 book, he states (as reported in Politico), 'there is a virtually unanimous scientific consensus among the hundreds of research scientists who have published peer-reviewed articles in the field that Thimerosal is immensely toxic to brain tissue.' Thimerosal, as a preservative gets metabolized as ethylmercury, which is distinct from the more toxic methylmercury. In large doses, both compounds can be toxic to the brain and kidney, resulting in tremors, memory loss, mood swings, depression, protein in the urine and kidney damage. However, ethylmercury poses a significantly decreased risk for humans because it has a much shorter half-life of less than week compared to methylmercury, which has a half-life of 1.5 months according to the World Health Organization. Ethylmercury is removed from the body fast and actively excreted into the gut, as oppose to methylmercury that can accumulate in the body and result in potential toxic effects. In 1999, because of scientific uncertainty at the time and theoretical concerns about thimerosal, the preservative was removed from nearly all childhood vaccines as a precautionary measure per the FDA, not because it was shown to cause any harm. The only childhood vaccine that still contains thimerosal in some formulations is the flu vaccine. Part of the reason thimerosal was removed from childhood vaccines was because an infant in the early 1990s receiving childhood vaccines could be exposed to a cumulative dose of mercury as high as 187.5 micrograms by the age of 6 months, which exceeded the guidelines put forth by the EPA, but not the WHO. Even at a dose of 187.5 micrograms of ethylmercury, no studies have shown adverse health effects or harm to humans, other than local skin reactions at the injection site of the vaccine, as shown in a study published in the journal Pediatrics. Despite what Secretary of HHS Kennedy has suggested, thimerosal has not been shown to cause autism. In fact both the FDA and multiple peer-reviewed scientific studies have asserted and shown no link between thimerosal use in vaccines and autism. The use of thimerosal in U.S. FDA licensed vaccines has significantly declined because of reformulations and the availability of vaccines in single-dose containers. Currently, a couple of flu vaccines are formulated to contain thimerosal, although the majority of flu vaccines that currently exist do not contain thimerosal. The ACIP will convene later this week to hold a vote on the status of thimerosal on vaccines. Even if completely removed from the flu vaccine, the vaccine will not 'become' safer, as decades of research has already shown thimerosal to be safe and effective as a preservative. Experts warn that holding the vote could cast doubt on vaccine uptake. Dr. Jeremy Faust, Editor-in-Chief of MedPage Today, writes, 'Elevating this debunked myth to national policy lends credence to misinformation, and sets the stage for other actions that may undermine vaccine confidence in the United States.'
